media center
March 18, 2021 Augustine Therapeutics appoints Sylvain Celanire as CEO to accelerate development of innovative medicines for rare neuromuscular diseases
December 16, 2019 VIB and KU Leuven announce new spin-off Augustine Therapeutics to fight neuromuscular diseases
March 19, 2021 Augustine Therapeutics strengthens Board of Directors and sets up Scientific Advisory Board
March 23, 2021 Augustine Therapeutics awarded EUR 1.2 million VLAIO research grant to develop new medicines for neuromuscular diseases